CPIX Earnings Date: Nov 3, 2026 (Estimated) — Cumberland Pharmaceuticals Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is CPIX's next earnings date?
Cumberland Pharmaceuticals Inc. (CPIX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $8.5M.
How did CPIX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Cumberland Pharmaceuticals Inc. posted EPS of -$0.20 versus the -$0.13 estimate, a miss of 53.8%. Revenue was $166,458 against a $8.5M estimate. The stock's 1-day post-earnings move was -2.8%.
How much does CPIX stock move after earnings?
CPIX beat EPS estimates in 0 of its last 1 reported quarter. Over the last 8 reports the stock moved an average of 8.6% (up or down) in the day after earnings.
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.13 | -0.20 | -53.85% | $166,458 | ❌ Miss | -2.83% | +2.45% | -16.09% |
| 2026-05-05 | Q1 2026 | — | -0.13 | — | $9.1M | — | -3.95% | -0.45% | +28.35% |
| 2026-03-03 | Q4 2025 | — | -0.01 | — | $13.7M | — | -19.87% | -30.99% | -32.32% |
| 2025-11-04 | Q3 2025 | — | -0.06 | — | $8.3M | — | -12.39% | -24.82% | -11.62% |
| 2025-08-05 | Q2 2025 | — | 0.02 | — | $10.8M | — | -15.31% | -23.20% | -3.44% |
| 2025-03-04 | Q4 2024 | — | -0.02 | — | $10.4M | — | +11.90% | -14.55% | -29.26% |
| 2024-11-07 | Q3 2024 | — | -0.02 | — | $9.1M | — | -0.83% | +0.00% | +3.34% |
| 2024-08-06 | Q2 2024 | — | 0.01 | — | $9.8M | — | -1.35% | -8.02% | -12.67% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $2.0M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product - Vibativ | 88.7% | $1.7M | -42.0% | $1.0M | $3.0M | $3.0M | $3.0M |
| Product - Other | 11.3% | $222K | -55.0% | $624K | $3.1M | $492K | $307K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.